Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 23, 2012

ORGANOVO HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 000-54621

 

Delaware   27-1488943

(State or other jurisdiction

of incorporation)

 

(I.R.S. Employer

Identification No.)

6275 Nancy Ridge Dr.,

San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 550-9994

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 7.01 Regulation FD Disclosure

Offer to Amend and Exercise Warrants

On November 16, 2012, Organovo Holdings, Inc. (the “Company”) filed a tender offer with respect to certain warrants to purchase common stock of the Company to provide the holders thereof with the opportunity to amend and exercise their warrants, upon the terms and subject to the conditions set forth in the Company’s tender offer statement on Schedule TO and the related exhibits included therein (the “Offering Materials”) filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2012.

Pursuant to the tender offer, the Company is offering to amend, upon the terms and subject to the conditions set forth in the Offering Materials, warrants to purchase an aggregate of 14,510,928 shares of common stock (the “Offer to Amend and Exercise”), including: (i) outstanding warrants to purchase 1,500,000 shares of the Company’s common stock issued to investors participating in the Company’s bridge financing completed in November 2011 (the “Bridge Warrants”); (ii) outstanding warrants to purchase 11,653,678 shares of the Company’s common stock issued to investors participating in the Company’s private placement financings closed on February 8, 2012, February 29, 2012 and March 16, 2012 (the “Investor Warrants”); and (iii) outstanding warrants to purchase 1,357,250 shares of the Company’s common stock issued to investors in the Company’s private placement transactions completed in 2011 (the “Private Warrants” and collectively with the Bridge Warrants and the Investor Warrants, the “Original Warrants”). There is no minimum participation requirement with respect to the Offer to Amend and Exercise.

Pursuant to the Offer to Amend and Exercise, the Original Warrants will be amended (the “Amended Warrants”) to: (i) reduce the exercise price of the Original Warrants from $1.00 per share to $0.80 per share of common stock in cash, (ii) shorten the exercise period of the Original Warrants so that they expire concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on December 17, 2012, as may be extended by the Company in its sole discretion (“Expiration Date”), (iii) delete the price-based anti-dilution provisions contained in the Bridge and Investor Warrants, (iv) restrict the ability of the holder of shares issuable upon exercise of the Amended Warrants to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any of these shares without the prior written consent of the Company for a period of time commencing on the holder’s exercise date and ending on the later of (a) the date that is twenty (20) days after exercise of the Warrant or (b) the date that is five business days after the Expiration Date (the “Lock-Up Period”); and (v) provide that a holder, acting alone or with others, will agree not to effect any purchases or sales of any securities of the Company in any “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any type of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) or similar arrangements, or sales or other transactions through non-U.S. broker dealers or foreign regulated brokers through the expiration of the Lock-Up Period. Other than set forth above, the terms of the Original Warrants will remain unmodified and in full force and effect.

The Offer to Amend and Exercise is limited to “accredited investors” as that term is defined in Rule 501 of the Securities Act of 1933, as amended (the “Securities Act”). Eligible holders may elect to amend some or all of their Original Warrants. If Original Warrant holders choose not to participate in the Offer to Amend and Exercise, their Original Warrants will remain in full force and effect, as originally issued.

The purpose of the Offer to Amend and Exercise is to encourage the amendment and exercise of the Original Warrants to help the Company reduce its outstanding warrant liability and to raise funds to support the Company’s operations by providing the holders of the Original Warrants with the opportunity to obtain and exercise an Amended Warrant by significantly reducing the exercise price of the Original Warrants.

Investor Presentation

On November 23, 2012, the Company made a presentation regarding the Company available to investors. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.


The information furnished on this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Important Information

The information in this Form 8-K is for informational purposes only, and the foregoing reference to the tender offer shall not constitute an offer to buy, exchange or amend securities or constitute the solicitation of an offer to sell, exchange or amend any of the Company’s securities. The Company filed a tender offer statement on Schedule TO and the offering materials related to the tender offer, including the Offer to Amend and Exercise, the Election to Participate and Exercise Warrant, forms of Amended Warrants and Notice of Withdrawal, with the SEC. These documents contain important information that should be read carefully and considered before any decision is made with respect to the tender offer. These documents may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, these documents (and all other materials filed by the Company with the SEC) may be obtained at no charge by directing a request to Organovo Holdings, Inc., 6275 Nancy Ridge Drive, San Diego, California 92121, Attn: Corporate Secretary, telephone number (858) 550-9994.

Organovo Holdings has retained Aegis Capital Corp. as its Warrant Agent for the tender offer. Aegis Capital may be reached at 810 7th Avenue, 18th Floor, New York, NY 10019, Attn: Adam K. Stern, Head of Private Equity Banking, telephone (646) 502-2401.

The tender offer is only being made to “accredited investors” as that term is defined in Rule 501 of the Securities Act. In addition, the tender offer is not being made to warrant holders in any U.S. state in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

Forward Looking Statements

This Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, contains “forward-looking statements.” All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to, statements regarding the potential benefits and future uses of the Company’s science and technology, the Company’s ability to develop products that can be used to improve drug development and the Company’s future product development opportunities. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The various risks and uncertainties that could cause the Company’s actual future results to differ materially from current expectations include, but are not limited to, those risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its science and technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s failure to achieve its business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including its current report on Form 8-K/A filed with the SEC on May 11, 2012. These forward-looking statements are made as of the date of this Current Report, and the Company does not undertake an obligation to update these forward-looking statements after such date.

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

99.1        Investor presentation dated November 23, 2012.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        ORGANOVO HOLDINGS, INC.
Date: November 23, 2012     /s/ Keith Murphy
    Keith Murphy
    President and Chief Executive Officer


EXHIBIT INDEX

 

Exhibit No.    Description
99.1    Investor presentation dated November 23, 2012.
Investor presentation
Changing the Shape of
Medical Research
and Practice
Keith Murphy
Chairman and Chief Executive Officer
0
©
Copyright 2012, Organovo Holdings, Inc.  This report is solely for the use of intended audience.  No part
of it may be circulated, quoted, or reproduced for distribution outside the organization without prior
written approval from Organovo Holdings, Inc.
Exhibit 99.1
November 23, 2012


SAFE HARBOR STATEMENT
1
©
Copyright 2012  Organovo Holdings, Inc.
OTC QX: ONVO
This
presentation
contains
“forward-looking
statements”
that
involve
significant
risks
and
uncertainties.
All
statements
other
than
statements
of
historical
fact
are
statements
that
could
be
deemed
forward-looking
statements,
including,
but
not
limited
to,
statements
regarding
the
results
and
benefits
of
the
Company’s
tender
offer
and
its
prospective
performance,
opportunities
and
business
outlook.
Any
forward-looking
statements
contained
herein
are
based
on
current
expectations,
but
are
subject
to
a
number
of
risks
and
uncertainties.
The
risks
and
uncertainties
that
could
cause
the
Company’s
actual
future
results
to
differ
materially
from
current
expectations
include,
but
are
not
limited
to,
risks
and
uncertainties
relating
to
the
Company's
ability
to
develop,
market
and
sell
products
based
on
its
technology;
the
expected
benefits
and
efficacy
of
the
Company’s
products
and
technology;
the
availability
of
substantial
additional
funding
for
the
Company
to
continue
its
operations
and
to
conduct
research
and
development,
clinical
studies
and
future
product
commercialization;
the
Company's
failure
to
achieve
its
business,
research,
product
development,
regulatory
approval,
marketing
and
distribution
plans
and
strategies;
and
the
successful
completion
of
the
tender
offer.
These
and
other
factors
are
identified
and
described
in
more
detail
in
the
Company’s
filings
with
the
SEC,
including
its
current
report
on
Form
8-K/A
filed
with
the
SEC
on
May
11,
2012.
These
forward-looking
statements
are
made
as
of
the
date
of
this
presentation,
and
the
Company
does
not
undertake an obligation to update these forward-looking statements after such date.


2
©
Copyright 2012  Organovo Holdings, Inc.


3
Organovo has made tremendous progress
In past 12 months
Signed up United Therapeutics
Delivered tissue blocks to Pfizer under our collaboration
NIH Grant for 3D liver
Successful financing and reverse merger
Attracted top executives and doubled staff
Opened 15,000 sq ft new facility
Completed Phase 1 market research
OTC QX uplist
©
Copyright 2012  Organovo Holdings, Inc.


4
Market research reveals opportunity
Cell Assay Products
Identified specific market opportunity >$500M by 2018
High unmet customer need and market opportunity
identified that can be met with 3D cell assay products
Overall cell biology market growing to $17B by 2016,
12% CAGR
Disease models
Qualitative market research conducted to target initial
opportunities –
including Oncology
Focus on Pharma co. “lead optimization”
as entry point
©
Copyright 2012  Organovo Holdings, Inc.
Source: 2012 Scientia Advisors market research, sponsored by Organovo


5
Organovo milestones in 2013
Organovo will keep delivering
Major new data on 3D liver by Q2 2013
Expanding the set of current partners
Reaching upstream in drug discovery to partner with
academics –
now pursuing partnerships
Technology partnerships to develop bioprinting
Collaborate with 3D peers in non-bio spaces
Company pursuing uplisting to NASDAQ or NYSE
©
Copyright 2012  Organovo Holdings, Inc.


6
Goals of tender offer
Clean up derivative liability
Outstanding warrants from Q1 offering create derivative
liability for company
Company currently is below shareholder equity
requirements for listing on NASDAQ or NYSE MKT
as a result
Raise funds
End Q3 Cash on hand $7.7M
Tender offer can raise up to $11.5M gross
Company net burn of ~$7-8M/year expected in 2013
Source: Scientia Advisors study, commissioned by company
©
Copyright 2012  Organovo Holdings, Inc.


Seeking uplisting to major exchange
7


Seeking uplisting to major exchange
8
NYSE MKT Initial Listing Standards


Organovo Contacts:
Keith Murphy, CEO
(858) 550-9993
kmurphy@organovo.com
Barry Michaels, CFO
(858) 224-1003
bmichaels@organovo.com
Website: 
http://www.organovo.com
9
Enabling tissue on demand
OTC QX: ONVO
©
Copyright 2012  Organovo Holdings, Inc.